1例直肠癌术后化疗致急性肾损伤的药学监护

doi:10.19803/j.1672-8629.2022.05.21

中国药物警戒 ›› 2022, Vol. 19 ›› Issue (5): 568-571.
DOI: 10.19803/j.1672-8629.2022.05.21

1例直肠癌术后化疗致急性肾损伤的药学监护

李亚昙, 马亮英

新疆医科大学第二附属医院药学部, 新疆维吾尔自治区乌鲁木齐830011

收稿日期:2020-07-14 出版日期:2022-05-15 发布日期:2022-05-18
作者简介:李亚昙,女,在读博士,副主任药师,临床药学。
基金资助:
新疆维吾尔自治区药学会科研基金资助项目（YXH201819）; 新疆维吾尔自治区乌鲁木齐市水磨沟区科技计划项目：某三甲医院吉西他滨超说明书现状调查临床药师干预措施研究

One case of acute renal injury caused by postoperative chemotherapy for rectal cancer

LI Yatan, MA Liangying

Dept. of Pharmacy, the Second Affiliated Hospital, Xinjiang Medical University , Urumqi Xinjiang 830011, China

Received:2020-07-14 Online:2022-05-15 Published:2022-05-18

摘要/Abstract

摘要： 目的参与并随访观察临床治疗中直肠癌患者术后化疗后发生急性肾损伤的全过程,为其发生药品不良反应后的治疗方案作出调整,探讨临床药师工作中的切入点。方法结合1例直肠癌患者术后化疗后出现药品不良反应的病例,针对其肾功能损伤的主要问题,临床药师运用临床药学知识及经验,对患者化疗前病情特点、治疗过程中及化疗后药品不良反应等多环节实施全程药学监护。结果通过对患者的化疗方案进行个体化调整,对患者肾功能损伤进行对症治疗,临床药师成功进行了对该患者的临床药学服务。结论临床药师在肿瘤患者用药治疗过程中,可利用临床药学专业协助临床医师对患者的个体化治疗提供技术支持,不仅充分服务于临床,还可实现临床合理用药。

关键词: 直肠癌, 化疗方案, 肾功能损伤, 药品不良反应

Abstract: Objective To retrospectively analyze the whole process of treating acute kidney injury after postoperative chemotherapy in a patient with rectal cancer so as to explore the role of clinical pharmacists. Methods Taking into consideration the adverse reactions of a rectal cancer patient after chemotherapy and his renal injury, the clinical pharmacist provided pharmaceutical care for the patient before chemotherapy, during treatment and after chemotherapy. Results Through individualized adjustment of the patient's chemotherapy regimen and symptomatic treatment of renal function injury, the clinical pharmacist was a great success in his effort to give clinical pharmaceutical care to the patient. Conclusion In the course of medication for a tumor patient, clinical pharmacists can use their knowledge and expertise to assist clinicians in providing technical support for individualized drug treatment, which can not only facilitate clinical practice, but also ensure rational medication.

Key words: rectal cancer, chemotherapy plan, renal injury, adverse drug reaction

中图分类号:

R994.11

李亚昙, 马亮英. 1例直肠癌术后化疗致急性肾损伤的药学监护[J]. 中国药物警戒, 2022, 19(5): 568-571.

LI Yatan, MA Liangying. One case of acute renal injury caused by postoperative chemotherapy for rectal cancer[J]. Chinese Journal of Pharmacovigilance, 2022, 19(5): 568-571.

参考文献

[1] RON DA, VERA R, Labandeira CM, et al.Maintenance treatment in metastatic colorectal cancer: in search of the best strategy[J]. Clinical and Translational Oncology, 2020, 22(5): 1205-1215.
[2] AL-HILLAN A, AL-BANAA K, MOHAMED M, et al.A case of late recurrence of colon cancer after curative treatment[J]. Cureus, 2020, 12(5): e8083.
[3] WU DH, WANG DS.Clinical etiology and risk factors of acute kidney injury[J]. Chinese Journal of Modern Medicine(中国现代医学杂志), 2015, 25(5): 61-65.
[4] FENG Z, CHEN XM.Prevention and treatment of acute kidney injury in China[J]. West China Medicine(华西医学), 2018, 33(7): 777-781.
[5] JIANG N, SUN L.Interpretation of expert consensus on ADQI acute kidney disease and Renal Recovery in 2017[J]. Chinese Journal of Nephropathy Research(中华肾病研究电子杂志), 2017, 6(6): 278-281.
[6] LI GH, YANG J.Clinical Work Manual of Oncology Pharmacists(肿瘤专科药师临床工作手册)[M]. Beijing: People's Medical Publishing House, 2018: 80-82.
[7] National Health and Family Planning Commission expert Committee on Rational Drug Use. Guidelines on rationa Drug Use for Gastrointestinal Malignancies[J]. Exploration of Rational Drug Use in China(中国合理用药探索), 2017, 14(9): 5-54.
[8] BONVENTRE JV YL.Cellular pathophysiology of ischemic acute kidney injury[J]. J Clin Invest, 2011, 121: 4210-4221.
[9] ZENG WQ, SHEN J, GONG Q.The path of armaceutical care for tumor therapy(肿瘤治疗药学监护路径)[M]. Shanghai: World Book Publishing Company, 2019: 71-73.
[10] FANG WT, GU YH.Drug selection for the treatment of colorectal cancer with complications[J]. Chinese Electronic Journal of Colorectal Diseases(中华结直肠疾病电子杂志), 2018, 7(5): 420-429.
[11] PINSKY PF, SCHOEN RE.Contribution of surveillance colonoscopy to colorectal cancer prevention[J]. Clinical Gastroenterology and Hepatology, 2020, 18(13): 2937-2944.
[12] LI QY, CHEN J, WANG G.Effects of "hidden kidney lesion" on the safety and efficacy of capecitabine in the treatment of advanced colorectal cancer[J]. Chinese Modern Applied Pharmacy(中国现代应用药学), 2014, 31(6): 748-751.
[13] ZHU JL, ZHOU YN, YUAN WZ, et al.Comparison of adverse reactions after neoadjuvant chemotherapy with oxaliplatin combined with tegor and oxaliplatin combined with capecitabine for gastric cancer[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2020, 17(1): 17-22.
[14] ZHAI SY, CUI R, et al.Analysis of 4120 adverse reactions of anti-umor drugs[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2014, 11(5): 291-294.
[15] ZHANG XM, CAI J.Drug analysis of renal injury aggravation in elderly patients with lung cancer undergoing chemotherapy[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2020, 17(8): 491-495.
[16] QIU YH, ZHONG HJ, FANG MY, et al.Recentterm efficacy of gemcitabine oxaliplatin in the treatment of 31 cases of advanced gastrointestinal tumors[J]. Journal of Oncology(肿瘤学杂志), 2004, 9(3): 175-176.

1例直肠癌术后化疗致急性肾损伤的药学监护

One case of acute renal injury caused by postoperative chemotherapy for rectal cancer

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	贾晋生, 刘红亮, 王青, 侯永芳, 李馨龄. 基于知识图谱联合ERNIE-DPCNN模型的药品不良反应自动关联性评价方法研究[J]. 中国药物警戒, 2024, 21(2): 163-166.
[2]	李应芬, 韩雷. 319例注射用脑蛋白水解物药品不良反应报告分析[J]. 中国药物警戒, 2024, 21(2): 195-198.
[3]	徐伟佳, 彭崎, 黄海渝, 张磊姣, 肖华, 吴雪. 285例新型抗肿瘤药物不良反应分析[J]. 中国药物警戒, 2024, 21(2): 199-203.
[4]	郭清华, 彭笑笑, 朱萍, 刘西霖, 杨颖华, 陈志海. 氨氯地平过量致多器官功能障碍综合征1例分析[J]. 中国药物警戒, 2024, 21(2): 204-207.
[5]	方美琳, 郑慧敏, 王存泽, 王凌, 阮君山. 注射用奥沙利铂致全身肌肉疼痛1例分析[J]. 中国药物警戒, 2024, 21(2): 208-210.
[6]	陈玉艳, 张明霞, 张涛, 张晋. 斯鲁利单抗注射液致间质性肺炎不良反应1例分析[J]. 中国药物警戒, 2024, 21(2): 213-215.
[7]	曹桂萍, 邓琳琳, 朱干红, 陆颖, 马爽, 陈玲玲, 刘丽丽. 天麻首乌片致严重肝损伤1例分析[J]. 中国药物警戒, 2024, 21(2): 216-218.
[8]	高云娟, 赵旭, 白天凯, 柏兆方, 王伽伯, 宋海波, 肖小河. 基于不良反应监测大数据的药品安全风险发现与识别策略[J]. 中国药物警戒, 2024, 21(1): 1-5.
[9]	郭龙鑫, 高云娟, 吴承钊, 龙敏娟, 祝胜凯, 宋海波, 赵旭, 肖小河. 基于不良反应监测大数据的中药药源性肝损伤风险信号新发现及易感因素初探[J]. 中国药物警戒, 2024, 21(1): 15-19.
[10]	蒋文硕, 杨莉. 694例癫痫医师药师联合门诊患者药品不良反应分析[J]. 中国药物警戒, 2024, 21(1): 102-106.
[11]	陈华炎, 江东波, 郭春连, 杨家琪, 黎雨欣, 蔡伟明. 326例奈玛特韦片/利托那韦片治疗新型冠状病毒感染安全性分析[J]. 中国药物警戒, 2024, 21(1): 107-110.
[12]	刘赛月, 吕小琴, 周耘. 疑似药品不良反应死亡病例调查及报告实施要点[J]. 中国药物警戒, 2023, 20(9): 971-974.
[13]	里筱竹, 王蔷, 逄瑜, 张轶菁. 个例药品不良反应报告管理浅析与思考[J]. 中国药物警戒, 2023, 20(9): 975-977.
[14]	逄瑜, 刘博, 吕少俐, 王涛, 邢颖, 秦星宇, 田月洁, 吴文宇. 基于国际药物警戒经验探讨收集患者报告的意义[J]. 中国药物警戒, 2023, 20(9): 978-981.
[15]	刘文东, 崔欢欢, 王晓晗, 苏娴, 王海学. 我国儿童用药临床试验期间药物警戒监管体系现状及思考[J]. 中国药物警戒, 2023, 20(9): 1002-1006.